Eli Lilly to acquire gene-editing biotech company Verve Therapeutics for $1.3 billion. Here's why
- Posted on June 17, 2025
- By Google News
- 1 Views
Eli Lilly to acquire gene-editing biotech company Verve Therapeutics for $1.3 billion. Here's why
US Big Pharma firm Eli Lilly & Co. agreed to buy gene-editing biotech company Verve Therapeutics Inc. for $1.3 billion as the drugmaker focuses its investments in experimental medicine for a potential long-term growth.
